QA1.791

Familial cancer syndrome with pathogenic BRCA2 mutation

Billable / specificNew in FY2027POA exempt

QA1.791 is a billable, specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes in FY2027.

Inclusion terms

Applicable to

  • BRCA2-cancer predisposition syndrome
  • Hereditary breast and ovarian cancer syndrome with pathogenic BRCA2 mutation

Includes (from QA1)

  • Note: Codes from this chapter are not for use on maternal records

Excludes2

Not included here — may be reported together when both conditions exist.

  • inborn errors of metabolism (E70-E88) (from QA1)
  • multiple endocrine neoplasia [MEN] syndromes (E31.2-) (from QA1)

Code also

An additional code may be needed.

  • , if applicable, any associated conditions, such as: (from QA1)
  • genetic susceptibility to malignant neoplasm by site (Z15.0-) (from QA1)
  • malignant neoplasms (C00.0-C96.9) (from QA1)
  • personal history of malignant neoplasm (Z85.-) (from QA1)

Also known as

  • BRCA2-cancer predisposition syndrome
  • Hereditary breast and ovarian cancer syndrome with pathogenic BRCA2 mutation
  • Syndrome, BRCA2-cancer predisposition
  • Syndrome, familial cancer, with pathogenic BRCA2 mutation
  • Syndrome, hereditary breast and ovarian cancer, with pathogenic BRCA2 mutation

Parent code

  • QA1.79Other inherited neoplasm predisposition syndrome of multiple systemsHeader

Related codes

  • QA1.790Familial cancer syndrome with pathogenic BRCA1 mutationBillable
  • QA1.792Li Fraumeni syndromeBillable
  • QA1.798Other inherited neoplasm predisposition syndrome of multiple systemsBillable

Browse